Obiettivo
Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ADA-SCID have been successfully treated with autologous gene corrected HSC, however, associated with safety issues inherent to first generation retroviral vectors. This project utilizes genetically modified HSC and their descendants as immunotherapeutic cells to build a healthy immune system in PID patients, and is carried out by clinical centres, scientists and industrial partners pioneering in the field of advanced therapies and aiming at broad clinical application of safe cell-based therapeutic products. Multicentre phase I/II clinical trials for SCID-X1 and WAS are ready to start. Disease targeted technology to cure ADA-SCID, V(D)J recombination defects and CGD by gene corrected HSC and novel approaches in IPEX and HLH to gene modify already committed cells will be investigated. Based on rigorous preclinical efficacy and toxicology evaluation, flanked by basic studies aimed at improving HSC homing capacity and thymic epithelium regeneration, new clinical trials will be implemented. The consortium will establish a technology platform to implement, harmonize and run controlled, standardized multicentre preclinical studies using state-of-the-art advanced therapy. Strict observance of good practice quality guidelines and regulation of medicinal product development will be ensured. The successful completion of the project will be instrumental to accomplish and broaden clinical application of medicinal products able to rebuild and modulate the immune system with an anticipated impact that extends beyond PID to acquired immune disorders, allogeneic HSCT and cancer treatment.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicinetoxicology
Argomento(i)
Invito a presentare proposte
FP7-HEALTH-2010-single-stage
Vedi altri progetti per questo bando
Meccanismo di finanziamento
CP-IP - Large-scale integrating projectCoordinatore
20132 Milano
Italia
Mostra sulla mappa
Partecipanti (19)
75654 Paris
Mostra sulla mappa
WC1E 6BT London
Mostra sulla mappa
60596 Frankfurt
Mostra sulla mappa
7610001 Rehovot
Mostra sulla mappa
01069 Dresden
Mostra sulla mappa
Partecipazione conclusa
3015 GD Rotterdam
Mostra sulla mappa
00165 Roma
Mostra sulla mappa
30625 Hannover
Mostra sulla mappa
20091 BRESSO MI
Mostra sulla mappa
51429 Bergish Gladbach
Mostra sulla mappa
4051 Basel
Mostra sulla mappa
78467 Konstanz
Mostra sulla mappa
69003 Lyon
Mostra sulla mappa
55743 IDAR OBERSTEIN
Mostra sulla mappa
06800 Cankaya Ankara
Mostra sulla mappa
8006 Zurich
Mostra sulla mappa
2333 AA Leiden
Mostra sulla mappa
3360 BIERBEEK
Mostra sulla mappa
20132 Milano
Mostra sulla mappa